InDex Pharmaceuticals Holding AB (publ) announced that a new method of use patent for the drug candidate cobitolimod has been granted by the Korean Intellectual Property Office. The patent provides protection for the use of cobitolimod in the treatment of inflammatory bowel disease. The patent (patent number: 10-2592716) will provide an exclusivity period until August 2040, with the possibility of up to 5 years patent term extension upon market approval.

Corresponding patent applications have previously been granted in Europe and Hong Kong and filed in additional strategically important patent territories globally.